Select Bibliography

Filter by any of these (after searching):

Duggan, David

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 4 items

Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

Duggan, David B , Petroni, Gina R , Johnson, Jeffrey L ... - - J Clin Oncol - 2003

Manuscript - Primary - Primary - Lymphoma - Alliance-8952

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Henderson, I Craig , Berry, Donald A , Demetri, George D ... - - J Clin Oncol - 2003

Manuscript - Primary - Primary - Breast - CALGB-9344

Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel

Liu, Minetta C. , Demetri, George D. , Berry, Donald A. ... - - Cancer Treat Rev - 2008

Manuscript - Secondary - Long-Term-Followup - Breast - Alliance-9141

Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B trial 9342.

Winer, Eric P , Berry, Donald A , Woolf, Susan , Duggan, David ... - - J Clin Oncol - 2004

Manuscript - Primary - Primary - Breast - CALGB-9342